Seres Therapeutics (MCRB) Misses Q1 EPS by 9c

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $8.48 million.

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Jefferies Reinstates Talen Energy (TLN) at Hold
• Stifel Starts Victrex Plc. (VCT:LN) (VTXPF) at Buy